| 31.3596 -0.61 (-1.91%) | 12-08 15:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 40.68 | 1-year : | 47.51 |
| Resists | First : | 34.83 | Second : | 40.68 |
| Pivot price | 30.59  |
|||
| Supports | First : | 25.79 | Second : | 20.2 |
| MAs | MA(5) : | 32.26 |
MA(20) : | 29.09 |
| MA(100) : | 17.73 |
MA(250) : | 0 | |
| MACD | MACD : | 3.1 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 69.5 |
D(3) : | 75.7 |
| RSI | RSI(14): 64 |
|||
| 52-week | High : | 34.83 | Low : | 4.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MBX ] has closed below upper band by 40.4%. Bollinger Bands are 47.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 32.08 - 32.24 | 32.24 - 32.38 |
| Low: | 29.61 - 29.77 | 29.77 - 29.93 |
| Close: | 31.68 - 31.96 | 31.96 - 32.22 |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Mon, 17 Nov 2025
Mbx Biosciences stock hits 52-week high at 26.5 USD - Investing.com
Thu, 06 Nov 2025
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Tue, 21 Oct 2025
Top Executive Makes Major Move with MBX Biosciences Stock! - TipRanks
Tue, 21 Oct 2025
Hawryluk P. Kent buys MBX Biosciences shares worth $272k - Investing.com
Fri, 26 Sep 2025
MBX Biosciences Announces Public Offering Agreement - TipRanks
Thu, 25 Sep 2025
MBX Biosciences stock falls after pricing upsized public offering - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 106.5 (%) |
| Shares Short | 4,630 (K) |
| Shares Short P.Month | 3,910 (K) |
| EPS | 7.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -24.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | 4.13 |
| PEG Ratio | 0 |
| Price to Book value | 3.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|